Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Post Hoc Analysis of Suprachoroidal CLS-TA Versus Real-World Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function
Steven Yeh, MD
Annual Meeting Talks
2021
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Clinical Trials Handbook
Nikolas JS London, MD, FACS, FASRS
Updates from the Field
2021

Category: Diabetic Retinopathy

See more